Dr Fiona Mack, Ph.D. United States

Our location in the Alexandria Center for Life Science enables us to combine our expertise with that of world class researchers here in a vibrant scientific environment.

The Roche Translational and Clinical Research Center (TCRC) is part of the Pharma Research and Early Development (pRED) organization, and will serve as the hub for pRED activities in North America, underscoring the center’s importance to pRED and Roche. The TCRC staff is comprised of highly experienced drug developers who are focused on early clinical development of Roche drug candidates. In addition to advancing Roche’s existing portfolio, the TCRC experts will aim to access external innovation by identifying collaborations ranging from very early discovery platforms through advanced stage molecules.

Roche Innovation Center
Pharmaceutical Research and Early Development 

Ms Kimberly Macleod United States

Provides psychiatric and wellness services to individuals seeking a healthy balance between mind and body. With an ever-increasing amount of medical research now linking brain chemistry with physical health, we strongly support a holistic approach to healthcare that integrates psychiatric and nutritional treatments and emphasizes whole-body wellness.

The founder of the Center is a psychiatrist with an extensive background in internal medicine. He has over twenty years of experience treating patients in the New York City area.

Integrative Center for Wellness
CAO 

Mr Paul Maddon United States

Maddon Advisors LLC
Founder 

Mr John Maddox United States

Infusion Pharma Consulting LLC

Infusion Pharma Consulting specializes in the orphan drug, hospital therapeutics and specialty biopharma markets.  Our key capabilities include strategic pricing and market access, business development, and brand strategy, supported by specialty markets research.  

We are leaders in the orphan drug and rare disease market and serve clients on four continents and in 12 countries.  Our clients range from start-ups to Top 5 companies.          

We look forward to discussing your needs.   

Infusion Pharma
Managing Director 

Mr Guy Maestre United States

Synaerion is committed to deliver tangible and decisive therapeutic interventions to patients with incurable neurologic disorders. Our technology leverages the therapeutic potential of a dual-target technology based on the disease-modifying potential of a key signal transduction brain factor. We are developing a new class of small molecules for the treatment of neurodegenerative disorders, initially amyotrophic lateral sclerosis (ALS aka Lou Gehrig Disease) and traumatic brain injury (TBI), expanding to Alzheimer’s disease and multiple sclerosis (MS). Therapeutic options for ALS and TBI patients are inadequate with only Rilutek® approved for ALS and none for TBI. Regenerative therapy (stem cell or mesenchymal cell transplants) is a promising new approach though still concerning for its "uncontrolled" mid/long-term safety. Synaerion's technology has the (upstream) benefit of a cell therapy with manageable long-term safety, combined with the ALS/TBI pathogenic target (downstream) effects. Synaerion's is the first and only disease-modifying dual-target technology tested in symptomatic ALS/TBI animals. We are developing two lead compounds for ALS and TBI, leveraging a rich pipeline for development in other therapeutic areas and a discovery research platform for novel NCEs.

More Information Website: http://www.synaerion.com

Synaerion Therapeutics, Inc.
Chief Operating Officer 

James Manfredi United States

At the Icahn School of Medicine at Mount Sinai, we are dramatically advancing the art and science of medical care through an atmosphere of intense collaborative learning, social concern, and scholarly inquiry.

We pursue innovative approaches to education, research and patient care, combining the best traditions of medicine with the principles and entrepreneurial thinking of a startup, to uncover novel insights about disease. Building this culture of innovation requires making large investments and taking a transformative approach to discovery, which means taking risks and disrupting the status quo. In this way, we are transforming the practice of medicine and reinventing medical research to produce radically better outcomes for patients.

We seek a variety of students who can contribute open-mindedness, empathy, social insight, medical, scientific, technological and engineering expertise, to change the very nature of medicine. We have developed a number of admissions and training programs to foster these advances and recruit multi-talented students from richly diverse backgrounds, in a non-traditional way.

We continually pioneer innovative approaches in our medical and graduate education curricula that instill entrepreneurism, encourage critical thinking and equip the next generation of basic and clinical scientists with cutting-edge methodological and technological skills to translate scientific discovery into practice and improve public health.

We have ambitious goals, preparing scientists, physicians, and leaders who will make significant contributions to local and global health care, remaining forever inquisitive in their quest for lifelong growth, learning, and contribution. We train in the classroom and the laboratory, at the bedside, and in the community. Our unwavering commitment to intellectual exchange, multidisciplinary teamwork, and innovation continually drives us forward in discoveries, advances, and service.

As a leader in biomedical research, we have hired accomplished scientists and executives with startup experience and melded them with Mount Sinai’s doctors and researchers, spurring new levels of collaboration among our faculty. We are an engine of discovery, creating new treatments for the patients who need them the most, working in partnership with leading high-tech companies.  We are on the threshold of a new era in precision medicine, and our mission is to cure diseases once thought incurable, changing the lives of patients worldwide.

Icahn School of Medicine at Mount Sinai, (MSSM)
Professor 

Mr Steve Manobianco United States

GENEWIZ is a leading global genomics service company. A full-service provider, GENEWIZ provides DNA sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory and clinical services. 

From the company’s founding, GENEWIZ has maintained its unwavering commitment to providing customers with the best value. Excelling in both science and customer support, GENEWIZ is dedicated to accelerating scientific discovery, as well as to developing and delivering innovative solutions for translational medicine and healthcare. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. 

At GENEWIZ, it is our mission to contribute to the advancement of life sciences and technologies. Together with our clients, we can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Our goal is to be the best in the world and the best for the world. 

Headquartered in South Plainfield, NJ, GENEWIZ is a privately-held global enterprise with locations in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; Langen, Germany; and Tokyo, Japan.

Specialties

DNA Sequencing; Gene Synthesis; Mutation Analysis; SNP Discovery; Sequencing from Bacteria and Phage; Difficult Template Sequencing; Plasmid Preparation; Site-directed Mutagenesis; Fragment Analysis

GENEWIZ
Vice President 

Mr Philippe C.M. Manteau United States

Schiff Hardin LLP
Partner 

Mr Thomas Marchand France

BIOMODEX
CEO 

Romain Marmot France

Voluntis With excellence and innovation at heart, Voluntis designs state-of-the-art mobile solutions for chronic and rare diseases to empower patients by embedding intelligence in smartphones and simplify care provision by powering health data management. Industry sectors E_health Therapeutics Area Cardiology / Vascular Diseases
Endocrinology
Oncology
Rare Disease
Your innovative solution

Our companion software embed patient-doctor connectivity and clinical intelligence into existing therapeutics or medical devices. We rely on our ISO-certified processes, medical algorithms and clinical studies of our software to create solutions that ensure safety and efficacy for our users.

Which problem are you solving ?

People suffering from chronic diseases often find themselves lost in their treatment protocols once they leave the doctor's office. They lack a way of communicating with their health care teams and the support to take the appropriate dose of medication, manage symptoms and control side effects.

Target market segments

Pharmaceutical companies / Health care payers / Medical device manufacturers

Key value proposition

Convergence of medical and technological solutions / Results backed by clinical trials / Quality and regulatory expertise / Extensive track record

Voluntis
Chief Operations Officer